English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Spinal inhibitory Ptf1a-derived neurons prevent self-generated itch

MPS-Authors
/persons/resource/persons255644

Escalante,  Augusto
Department: Molecules-Signaling-Development / Klein, MPI of Neurobiology, Max Planck Society;

/persons/resource/persons38927

Klein,  Rüdiger
Department: Molecules-Signaling-Development / Klein, MPI of Neurobiology, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

1-s2.0-S221112472031411X-main.pdf
(Publisher version), 5MB

Supplementary Material (public)

ScienceDirect_files_11Jan2021_13-04-03.346.zip
(Supplementary material), 8MB

Citation

Escalante, A., & Klein, R. (2020). Spinal inhibitory Ptf1a-derived neurons prevent self-generated itch. Cell Reports, 33(8): 108422. doi:10.1016/j.celrep.2020.108422.


Cite as: https://hdl.handle.net/21.11116/0000-0007-A8C8-A
Abstract
Chronic itch represents an incapacitating burden on patients suffering from a spectrum of diseases. Despite recent advances in our understanding of the cells and circuits implicated in the processing of itch information, chronic itch often presents itself without an apparent cause. Here, we identify a spinal subpopulation of inhibitory neurons defined by the expression of Pill a, involved in gating mechanosensory information self-generated during movement. These neurons receive tactile and motor input and establish presynaptic inhibitory contacts on mechanosensory afferents. Loss of Pill a neurons leads to increased hairy skin sensitivity and chronic itch, partially mediated by the classic itch pathway involving gastrin-releasing peptide receptor (GRPR) spinal neurons. Conversely, chemogenetic activation of GRPR neurons elicits itch, which is suppressed by concomitant activation of Pill a neurons. These findings shed light on the circuit mechanisms implicated in chronic itch and open novel targets for therapy developments.